Clinical Trial

Add-on Buprenorphine at Analgesic Doses for the Treatment of Severe Suicidal Ideas During a Major Depressive Episode

Study acronym: BUPRIS
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims at investigating if adjunctive buprenorphine at low dose to treatment as usual is effective in reducing severe suicidal ideas in major depressive episode, and at determining the most effective dose.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2018-08-22; most recent amendment 2025-08-19.
Status change: Not Yet Recruiting → Recruiting 2021-07-08
Trial Details
NCT Number NCT03646058
Lead Sponsor Centre Hospitalier Universitaire de Nīmes
Conditions Suicidal Ideation, Major Depressive Episode
Enrollment 180 participants
Start Date 2021-10-10
Primary Completion 2026-10 (estimated)
Study Completion 2027-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-21